Risk calculation for hyperkalaemia in heart failure patients

Netherlands Journal of Medicine

Volumn 65, Issue 6, 2007, Pages 208-211

  Vereijken, T L J ^a   Bellersen, L ^a   Groenewoud, J M M ^a   Knubben, L ^a   Baltussen, L ^a   Kramers, C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus; Heat failure; Hyperkalaemia; Renal failure; Risk factors

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM;

ADULT; AGE; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG USE; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT MONITORING; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TERTIARY HEALTH CARE;

AGED; DIABETES COMPLICATIONS; EPISODE OF CARE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 34347236141     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9.
2. Pitt B, Zannad F, Remme WJ, et al. The Randomized Aldactone Evaluation Study. The effect ofspironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
3. Juurlink DN, Muhammad MM, Lee DS, et al. Rates of hyperkalemia after publication ofthe randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
4. Berry C, McMurray JJV. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:8-10.
5. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148:971-8.
6. Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003;327:147-9.
7. Pedone C, Corsonello A, Antonelli R, et al. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006;35:121-6.
8. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005;30:233-9.
9. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary. Eur Heart J 2005;26:1115-40.
10. Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ 2005;173:40-5.